The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.

Detailed Description

Not Provided

Study Type

Observational

Study Design

Observational Model: CohortTime Perspective: Prospective

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Non-Probability Sample

Study Population

Ambulatory or hospitalized patients coming from the cardiology clinic of the participating hospitals

Condition

Atrial Fibrillation

Intervention

Drug: Rivaroxaban (Xarelto, BAY59-7939)

15 mg OD or 20 mg OD

Study Groups/Cohorts

Rivaroxaban

Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)

Publications *

Not Provided

* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status

Completed

Enrollment

106

Completion Date

December 2014

Primary Completion Date

October 2014 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

Adult patients ≥ 18 years old with a confirmed diagnosis of non-valvular atrial fibrillation

Patients must in addition present with at least one of following risk factors: